Načítá se...
Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study
BACKGROUND: Sodium‐glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the s...
Uloženo v:
| Vydáno v: | Clin Cardiol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley Periodicals, Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6489772/ https://ncbi.nlm.nih.gov/pubmed/29663436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22899 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|